These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 17635895)

  • 41. The role of litigation in defining drug risks.
    Kesselheim AS; Avorn J
    JAMA; 2007 Jan; 297(3):308-11. PubMed ID: 17227983
    [No Abstract]   [Full Text] [Related]  

  • 42. Statistical Mining of Potential Drug Interaction Adverse Effects in FDA's Spontaneous Reporting System.
    Harpaz R; Haerian K; Chase HS; Friedman C
    AMIA Annu Symp Proc; 2010 Nov; 2010():281-5. PubMed ID: 21346985
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Outlier removal to uncover patterns in adverse drug reaction surveillance - a simple unmasking strategy.
    Juhlin K; Ye X; Star K; Norén GN
    Pharmacoepidemiol Drug Saf; 2013 Oct; 22(10):1119-29. PubMed ID: 23832706
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Detection of adverse drug reactions using hospital databases-a nationwide study in Portugal.
    Miguel A; Bernardo Marques ; Freitas A; Lopes F; Azevedo L; Pereira AC
    Pharmacoepidemiol Drug Saf; 2013 Aug; 22(8):907-13. PubMed ID: 23761351
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Importance and challenges of studying marketed drugs: what is a phase IV study? Common clinical research designs, registries, and self-reporting systems.
    Glasser SP; Salas M; Delzell E
    J Clin Pharmacol; 2007 Sep; 47(9):1074-86. PubMed ID: 17766697
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Analysis of spontaneous adverse drug reaction (ADR) reports using supplementary information.
    Ghosh P; Dewanji A
    Stat Med; 2011 Jul; 30(16):2040-55. PubMed ID: 21544847
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Nordic prescription databases as a resource for pharmacoepidemiological research--a literature review.
    Wettermark B; Zoëga H; Furu K; Korhonen M; Hallas J; Nørgaard M; Almarsdottir A; Andersen M; Andersson Sundell K; Bergman U; Helin-Salmivaara A; Hoffmann M; Kieler H; Martikainen J; Mortensen M; Petzold M; Wallach-Kildemoes H; Wallin C; Sørensen H
    Pharmacoepidemiol Drug Saf; 2013 Jul; 22(7):691-9. PubMed ID: 23703712
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Reporting Adverse Drug Events.
    Feagins LA; Abdelsayed GG; Schairer J;
    Am J Gastroenterol; 2019 Sep; 114(9):1411-1413. PubMed ID: 31464745
    [No Abstract]   [Full Text] [Related]  

  • 49. FDA Encourages Reporting of Tobacco Product Adverse Experiences.
    Retzky SS
    Chest; 2016 Dec; 150(6):1169-1170. PubMed ID: 27938736
    [No Abstract]   [Full Text] [Related]  

  • 50. Consumer Healthcare Products Association response to Major et al., "Trends in rates of acetaminophen-related adverse events in the United States", Pharmacoepidemiology & Drug Safety, May 2016, 25: 590-8.
    Sirois JE
    Pharmacoepidemiol Drug Saf; 2017 Mar; 26(3):353-354. PubMed ID: 28247547
    [No Abstract]   [Full Text] [Related]  

  • 51. Who is now responsible for discovering and warning about adverse effects of generic drugs?
    Kesselheim AS; Green MD; Avorn J
    JAMA; 2013 Sep; 310(10):1023-4. PubMed ID: 23922000
    [No Abstract]   [Full Text] [Related]  

  • 52. Use of a spontaneous adverse drug events database for identification of unanticipated drug benefits.
    Brinker A; Beitz J
    Clin Pharmacol Ther; 2002 Jan; 71(1):99-102. PubMed ID: 11823762
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Monitoring and managing adverse drug reactions.
    Fincham JE
    Am Pharm; 1992 Feb; NS32(2):74-81. PubMed ID: 1546634
    [No Abstract]   [Full Text] [Related]  

  • 54. Documenting an adverse drug reaction.
    Smith LS
    Nursing; 2005 Oct; 35(10):22. PubMed ID: 16205246
    [No Abstract]   [Full Text] [Related]  

  • 55. Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Matthews EJ; Kruhlak NL; Weaver JL; Benz RD; Contrera JF
    Curr Drug Discov Technol; 2004 Dec; 1(4):243-54. PubMed ID: 16472241
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Development of a mother-child database for drug exposure and adverse event detection in the Military Health System.
    Taylor LG; Thelus Jean R; Gordon G; Fram D; Coster T
    Pharmacoepidemiol Drug Saf; 2015 May; 24(5):510-7. PubMed ID: 25833769
    [TBL] [Abstract][Full Text] [Related]  

  • 57. IOM panel mulls over adverse-event reporting.
    Young D
    Am J Health Syst Pharm; 2005 Dec; 62(24):2590-1. PubMed ID: 16333055
    [No Abstract]   [Full Text] [Related]  

  • 58. The US Food and Drug Administration's Sentinel Initiative: expanding the horizons of medical product safety.
    Robb MA; Racoosin JA; Sherman RE; Gross TP; Ball R; Reichman ME; Midthun K; Woodcock J
    Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():9-11. PubMed ID: 22262587
    [No Abstract]   [Full Text] [Related]  

  • 59. Automated support for pharmacovigilance: a proposed system.
    Bright RA; Nelson RC
    Pharmacoepidemiol Drug Saf; 2002 Mar; 11(2):121-5. PubMed ID: 11998536
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Linking publication about efalizumab effectiveness with safety concerns.
    Robinson JK
    Arch Dermatol; 2009 Nov; 145(11):1338. PubMed ID: 19917976
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.